Classical Ayurvedic terminology should be preserved rather than converted into unsupported biomedical claims. Terms such as varṇya, śoṇitasthāpana, and kuṣṭhaghna describe actions and therapeutic categories within Ayurveda. They do not by themselves establish that Mañjiṣṭhā “detoxifies” blood, drains lymph, treats autoimmune disease, or cures a modern dermatological diagnosis. Appropriate use depends on the patient, formulation, plant part, dose, and clinical context.

Identity and Classical Ayurvedic Profile

Charaka Saṃhitā, Sūtrasthāna 4, includes Mañjiṣṭhā among the ten drugs of the varṇya mahākaṣāya, the group associated with supporting a healthy complexion. The API monograph provides a broader official profile for Mañjiṣṭhā stem and records the following attributes and actions.

The same API monograph lists therapeutic-use categories including yoni roga, śleṣmaja śotha, raktātisāra, kuṣṭha, visarpa, prameha, bhagna, arśa, and vyaṅga. These terms should not be reduced to one-to-one modern diagnoses. For example, kuṣṭha is a broad Ayurvedic category of skin disorders, while prameha encompasses a classical group of urinary and metabolic presentations rather than serving as a synonym for one disease.

Phytochemical Profile

Rubia cordifolia contains a chemically diverse mixture, and a 2022 comprehensive review catalogued more than 100 reported constituents. Major groups include anthraquinones, anthraquinone glycosides, naphthoquinones, naphthoquinone glycosides, bicyclic hexapeptides, triterpenoids, and polysaccharides. Composition varies with the plant part, origin, extraction solvent, and analytical method.

• Anthraquinones: Reported constituents include alizarin, munjistin, rubiadin, purpurin, tectoquinone, and xanthopurpurin. These compounds contribute to the plant’s pigment chemistry and have been examined in laboratory models for antimicrobial, cytotoxic, antioxidant, and inflammatory-pathway effects.
• Naphthoquinones: Mollugin is one of the most frequently investigated isolated compounds. In LPS-stimulated RAW264.7 macrophages, mollugin reduced nitric oxide release and expression of iNOS, IL-1β, and IL-6 while affecting JAK–STAT signalling. A later investigation examined mollugin in macrophages and a mouse model of sepsis through TAK1–NF-κB/MAPK and Nrf2-related pathways.
• Bicyclic peptides: The plant contains characteristic RA-series bicyclic hexapeptides. In a 2021 cancer-signalling reporter assay, deoxybouvardin, also called RA-V, strongly affected Wnt, Myc, and Notch pathways, whereas tested anthraquinones, including purpurin, showed mild or no inhibition in those assays. These were laboratory findings, not clinical cancer-treatment results.
• Other constituents: Anthraquinone and naphthoquinone glycosides, triterpenoids, and polysaccharides are also reported. The biological activity of a crude extract cannot be assigned automatically to one constituent or translated directly into a therapeutic dose.

Most modern pharmacological work on Mañjiṣṭhā remains preclinical. Cell-line and animal findings can identify possible biological actions, but they do not establish that an oral Mañjiṣṭhā product prevents or treats cancer, rheumatoid arthritis, psoriasis, eczema, acne, endometriosis, uterine fibroids, or lymphatic disease in humans.

Skin and Complexion

The strongest classical basis for discussing Mañjiṣṭhā in skin care is its inclusion in Charaka’s varṇya group and the API actions varṇya and kuṣṭhaghna, together with the listed use categories kuṣṭha, visarpa, and vyaṅga. These support its traditional selection in individualised Ayurvedic management of complexion changes and certain skin presentations, often as one ingredient within a larger formulation.

Laboratory evidence relevant to acne is limited. A 2003 in-vitro paper found that extracts of several Indian medicinal plants, including Rubia cordifolia, suppressed reactive oxygen species generated by neutrophils stimulated with Cutibacterium acnes, then named Propionibacterium acnes. A 2024 publication evaluated a polyherbal gel containing Rubia cordifolia, Aloe barbadensis, and Allium cepa; its results cannot be attributed to Mañjiṣṭhā alone or used as evidence for a stand-alone oral extract. Persistent acne, spreading rashes, infected lesions, unexplained bruising, or changing pigmented lesions require medical assessment.

Inflammation, Swelling, and Immune Pathways

The API describes Mañjiṣṭhā as śothaghna and lists śleṣmaja śotha among its therapeutic-use categories. Modern experiments provide limited mechanistic context: mollugin and 1-hydroxytectoquinone have reduced selected inflammatory mediators in cultured immune cells, and mollugin has also been studied in animal models. These findings concern isolated compounds at experimental concentrations and are not equivalent to clinical efficacy in autoimmune disorders.

Mañjiṣṭhā should not be presented as a replacement for disease-modifying antirheumatic drugs, corticosteroids, biologic medicines, antibiotics, or other prescribed treatment. People with inflammatory arthritis, fever, marked swelling, severe pain, organ involvement, or a diagnosed autoimmune condition should use any Ayurvedic adjunct only with coordinated supervision from qualified practitioners and the treating medical specialist.

Rakta, Menstrual, and Bleeding-Related Contexts

The API records śoṇitasthāpana, stambhana, and ārtavajanana, and lists yoni roga and raktātisāra among its therapeutic-use categories. This combination reflects the contextual nature of Ayurvedic prescribing: the same drug may be selected differently according to doṣa, tissue involvement, stage, formulation, and accompanying ingredients. It does not justify self-treatment of heavy menstrual bleeding, bleeding during pregnancy, blood in stool or urine, or unexplained anaemia.

Heavy or abnormal menstrual bleeding can accompany conditions affecting the uterus or ovaries, bleeding disorders, and the use of medicines such as anticoagulants. Medical evaluation is important when bleeding persists, disrupts normal life, occurs between periods or after sex, or is accompanied by severe pain. Mañjiṣṭhā should not be used to delay diagnosis.

Forms, Formulations, and Dose

Traditional use is formulation-specific. The official API dose for the pharmacopoeial dried stem drug is 2–4 g, but this amount should not be transferred to concentrated extracts, tinctures, proprietary tablets, or products made from another plant part. Extract ratios and marker-compound concentrations can alter exposure substantially.

Safety, Quality, and Precautions

Human pharmacokinetic and safety information for Rubia cordifolia is limited. The 2022 review identified a shortage of clinical safety data and described toxicity signals from animal experiments involving a fruit extract and the isolated anthraquinone rubiadin. These findings do not define a human toxic dose, but they support avoiding prolonged, high-dose, or poorly characterised self-medication.

• Pregnancy, breastfeeding, and children: Use only when specifically advised by an appropriately qualified clinician because reliable safety and dosing data are insufficient.
• Warfarin and other anticoagulants: General warfarin guidance recommends caution and additional INR monitoring when botanical products are started or stopped. Do not add Mañjiṣṭhā without review by the prescribing clinician or anticoagulation service.
• Liver or kidney disease: Avoid unsupervised use, particularly of concentrated extracts or multi-herb products, and disclose all supplements to the treating clinician.
• Product quality: Choose a correctly identified botanical product from a reputable manufacturer. The API stem monograph does not authenticate every commercial “Manjistha extract,” especially products made from different plant parts.
• Topical use: Patch-test a small area first and stop if irritation develops. Do not apply an unsterile paste to broken, infected, or weeping skin.

For companion reading, see our guides to Kaishore Guggulu, Ayurvedic decoctions and anti-inflammatory teas, and skin support during medical treatment.

Mañjiṣṭhā may be used as part of individualised Ayurvedic care, but it should not replace dermatological, gynaecological, rheumatological, oncological, or other necessary medical treatment. Consult a qualified Ayurvedic practitioner and a healthcare provider before using it for a diagnosed condition, during pregnancy, with prescription medicines, or for persistent or severe symptoms.

References

1. Ayurvedic Pharmacopoeia of India
2. Ayurvedic Pharmacopoeia of India
3. Charaka Samhita — Shadvirechanashatashritiya Adhyaya
4. Archive (archive.org)
5. Frontiersin (frontiersin.org)
6. Mollugin inhibits the inflammatory response in lipopolysaccharide-stimulated RAW264.7 macrophages by blocking the Janus kinase-signal transducers and activators of transcription signaling pathway (2013), PubMed
7. Mollugin prevents CLP-induced sepsis in mice by inhibiting TAK1-NF-κB/MAPKs pathways and activating Keap1-Nrf2 pathway in macrophages (2023), PubMed
8. Mdpi (mdpi.com)
9. Inhibition of Propionibacterium acnes-induced mediators of inflammation by Indian herbs (2003), PubMed
10. Polyherbal Antiacne Gel: In Vitro Antibacterial Activity and Efficacy Evaluation Against Cutibacterium acnes (2024), PubMed
11. Health (health.ucsd.edu)
12. NHS